- home
- about us
- Investment Approach
- Client Service Approach
- Market Analysis Summary
- Mission Statement
- Value Proposition
- Team Biographies
- Firm ADV PDFs
- Form CRS
- Firm Brochure-Part 2A of Form ADV
- Brochure Supplement Amit Stavinsky
- Brochure Supplement Frank Parks
- Brochure Supplement Dominick Savo
- Brochure Supplement Richard Mason
- Brochure Supplement Joe Estes
- Brochure Supplement Jonathan Ezra
- Statement Of Financial Strength
- Job Opportunities
- Letter to Clients
- member log-in
- contact us
Latest News about Novo Nordisk
Recent news which mentions Novo Nordisk
Slowdown in GLP-1 Sales Sends Novo Nordisk Stock Lower
August 06, 2025
Tickers
NEWS
From Wall Street Pit
Tickers
NEWS
From Wall Street Pit
From Benzinga
From Benzinga
Netflix, UnitedHealth, Novo Nordisk, Tesla And Trump Media: Why These 5 Stocks Are On Investors' Radars Today
April 17, 2025
From Benzinga
Nasdaq-Traded Cannabinoid Biotech Corbus Pharma Stock Plunges 60%, But Analysts Say 'Buy The Dip' Now
September 23, 2024
From Benzinga
Bernie Sanders Questions Why Your Monthly Ozempic Prescription Costs More Than A Luxury Handbag When It Can Be Sold For Less Than $100
September 22, 2024
From Benzinga
Corbus Pharma (CRBP) Stock Drops 60% After Novo Nordisk's Cannabinoid-Based Weight Loss Drug Trial Disappoints
September 20, 2024
From Benzinga
From Benzinga
Rivian, Lucid, Micron Technology, Novo Nordisk, Tesla: Why These 5 Stocks Are On Investors' Radars Today
June 25, 2024
From Benzinga
Chinese Generic Ozempic, Wegovy Versions Could Put Novo Nordisk At The Risk Of Stiff Competition In Key Market
June 05, 2024
From Benzinga
From Benzinga
US Health Agency Reviews Novo Nordisk's Wegovy For Potential Use In Treating Heart Disease Patients With Obesity
March 12, 2024
From Benzinga
Ozempic Maker Novo Nordisk To Introduce Obesity Drug Wegovy In Japan, Acknowledging Country's Rising Weight Issue
March 07, 2024
From Benzinga
Jim Cramer Says Nvidia, Eli Lilly, Novo Nordisk Are Not Overvalued: 'Will Be Ready To Buy If This Market Sells Off'
March 05, 2024
From Benzinga
Ozempic Maker's Parent Company To Invest $7B Annually By 2030: 'We Have More Money Than Ever To Invest'
February 12, 2024
From Benzinga
Ozempic Maker Strikes $11B Deal With Catalent As It Rushes To Meet Massive Weight-Loss Drug Demand
February 05, 2024
From Benzinga
Novo Nordisk Skyrockets To $506B Valuation Driven By 'Miracle' Drugs Ozempic, Wegovy
January 31, 2024
From Benzinga
From Benzinga
Jim Cramer Highlights 'Transformational' Impact Of Weight Loss Drugs Like Ozempic: Focus Now On 'Potential Winners' From The Same Narrative
December 04, 2023
From Benzinga
Tempest Therapeutics, Microsoft, Birkenstock, Novo Nordisk, Tesla: Why These 5 Stocks Are On Investors' Radars Today
October 11, 2023
From Benzinga
Wegovy Maker Novo Nordisk, Akero Therapeutics, Eli Lilly, Athena Consumer Acquisition, Tesla: Why These 5 Stocks Are Trending Today
October 10, 2023
From Benzinga
Snacks In The Ozempic Era: Food, Beverage Stocks Crash With Weight Loss Drugs On The Rise
October 06, 2023
From Benzinga
Novo Nordisk Eyes Social Inequality To Enhance Access To Wegovy: 'Have To Be More Intentional'
August 25, 2023
Tickers
NVO
From Benzinga
Darcey Silva Accused Of Using 'Miracle' Drug Ozempic After Showing Dramatic Weight Loss
August 25, 2023
From Benzinga
Ozempic Competitor Wegovy Could Prevent 1.5M Heart Attacks And Strokes Over 10 Years, Study Reveals
August 16, 2023
Tickers
NVO
From Benzinga
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.